Peptide R (TFA)

CAT: 0804-HY-P4111A-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-P4111A-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research[1][2][3].
UNSPSC
12352209
Target
CXCR
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Field of Research
Cancer
Purity
98.34
Smiles
O=C(N[C@@H](C)C(N[C@@H](CSSC[C@@H](C(O)=O)NC1=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC2=CC=CC=C2)C(N[C@H]1CC3=CC=CC=C3)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N.OC(C(F)(F)F)=O.[x]
Molecular Formula
C39H57N13O8S2.xC2HF3O2
Molecular Weight
900.08 (free base)
References & Citations
[1]Giulia Guidotti, et al. Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An Overview. Cells. 2020 Feb 20;9 (2) :490. |[2]Vadim Le Joncour, et al. Seek & Destroy, use of targeting peptides for cancer detection and drug delivery. Bioorg Med Chem. 2018 Jun 1;26 (10) :2797-2806.|[3]Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
CXCR4

Popular Products